Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study
Prevalence of gBRCA PV was highest among patients with high tumor RS, but not negligible in patients with intermediate and low tumor RS. Wider implementation of genetic testing, irrespective of ODX RS, could help optimize the management of patients with HR-positive/HER2-negative early breast cancer.
Authors
- Filipa C. Lynce (ORCID: https://orcid.org/0000-0001-6615-7076)
- Ann H. Partridge (ORCID: https://orcid.org/0000-0002-4722-4824)
- Linlin Luo (ORCID: https://orcid.org/0000-0002-0672-4267)
- Rabia Khan (ORCID: https://orcid.org/0000-0003-1338-3568)
- Luis C. Berrocal-Almanza (ORCID: https://orcid.org/0000-0003-1634-9971)
- Stefania Morganti (ORCID: https://orcid.org/0000-0001-5284-9944)
- Xiaoqing Xu (ORCID: https://orcid.org/0000-0002-7918-5129)
- Miguel Miranda
Institutions
- AstraZeneca (United Kingdom) (GB)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1007/s40487-025-00332-8
- Citations
- 3
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- Merck Sharp and Dohme